key: cord-1008487-2hh87kav
authors: Parauda, Sarah C.; Gao, Virginia; Gewirtz, Alexandra N.; Parikh, Neal S.; Merkler, Alexander E.; Lantos, Joshua; White, Halina; Leifer, Dana; Navi, Babak B.; Segal, Alan Z.
title: Posterior reversible encephalopathy syndrome in patients with COVID-19
date: 2020-07-09
journal: J Neurol Sci
DOI: 10.1016/j.jns.2020.117019
sha: 054fec90d0032253ac7c000e8d3f53510ea04357
doc_id: 1008487
cord_uid: 2hh87kav

OBJECTIVE: To report four patients with coronavirus disease 2019 (COVID-19) who developed posterior reversible encephalopathy syndrome (PRES). METHODS: Patient data was abstracted from medical records at Weill Cornell Medical Center. RESULTS: Four patients with SARS-CoV-2 infection and PRES were identified. The patients' ages ranged from 64 to 74 years, and two were women. All four patients were admitted to the hospital with acute respiratory distress syndrome requiring intensive care unit admission and mechanical ventilation. PRES was diagnosed after persistent confusion, lethargy, new focal neurological deficits, or seizures were noted, with evidence of seizures on electroencephalogram for two of the patients. Imaging confirmed the presence of cerebral vasogenic edema. All four patients had elevated blood pressure and renal injury in the days preceding PRES diagnosis, as well as evidence of systemic inflammation and systemic hypercoagulability. Symptoms of PRES improved with blood pressure control. CONCLUSIONS: Our four cases demonstrate the occurrence of PRES in critically-ill patients with COVID-19. PRES should be considered in the differential for acute neurological deficits and seizures in this setting.

Posterior reversible encephalopathy syndrome (PRES) is a spectrum of radiologic and clinical findings unified by acute neurological symptoms and associated cerebral vasogenic edema. PRES is thought to occur from disordered cerebrovascular autoregulation and is associated with acute renal failure, acute hypertension, inflammatory and autoimmune conditions, select immunomodulatory medications, and endothelial injury 1, 2 . Many of these processes, as well as ischemic stroke, have been observed in SARS-CoV-2 infection 3,4 , yet little is known about the occurrence of PRES in this context. We present clinical and radiographic characteristics of four patients with PRES and SARS-CoV-2 infection. The Weill Cornell Medicine Institutional Review Board approved this study and waived the requirement for informed consent.

A 64-year-old man presented with hypoxic respiratory failure requiring intubation and neuromuscular blockade five days after symptom onset. He was treated with hydroxychloroquine. He developed acute renal failure with a peak serum creatinine of 5.67 mg/dL requiring continuous veno-venous hemodialysis, and had acute hypertension with peak mean arterial pressure 128 mm Hg and peak systolic pressure of 187 mm Hg (Figure 1A Table) . He had a right internal jugular deep vein thrombosis treated with heparin anticoagulation. He also had ongoing encephalopathy initially characterized by Figure 1A ). At discharge, he was alert and oriented, though inattentive, and had a right homonymous hemianopsia.

A 73-year-old man presented with a five-day history of dyspnea and cough and was found to have hypoxic respiratory failure requiring intubation and neuromuscular blockade. He was treated with hydroxychloroquine. His hospitalization was complicated by multiple infections and acute renal failure with creatinine peak of 2.04 mg/dL ( Figure   1B Table) , and myocardial infarction. He was encephalopathic and treated for presumed alcohol withdrawal with benzodiazepines and for delirium with antipsychotics. Six weeks into his hospitalization, he was noted to be persistently hypertensive with a maximum mean arterial pressure of 135 mm Hg and a maximum systolic pressure of 212 mm Hg oriented and followed all commands, with no focal neurologic deficits.

A 65-year-old woman with hypertension and diabetes was admitted and intubated with hypoxic respiratory failure after two weeks of dyspnea and cough. She was treated with hydroxychloroquine. She developed bacterial pneumonia with mean arterial pressure as high as 138mm Hg, systolic blood pressure up to 190 mm Hg, and a peak serum creatinine of 2.48 mg/dL ( Figure 1C Table) . Although her respiratory failure improved, she remained stuporous with repetitive blinking after sedation was weaned. CT showed symmetric hypoattenuation involving the bilateral occipital subcortical white matter. MRI showed corresponding non-enhancing T2 hyperintensities without diffusion restriction ( Figure 1C ). Routine EEG did not demonstrate any epileptiform activity. Blood pressure was controlled with improvement in her level of arousal and radiographic findings. At discharge, she did not have focal neurologic deficits, but she had mild cognitive deficits and temporal disorientation on formal neuropsychologic testing.

A 74-year-old woman with hypothyroidism, diabetes, and hyperlipidemia presented with eight days of cough, fever and progressive dyspnea. She required endotracheal intubation and mechanical ventilation for two weeks. Her hospitalization was notable for mild transaminitis, an elevated creatinine that peaked at 1.61 mg/dL, persistent respiratory failure requiring paralysis and proning, acute hypertension with a maximum mean arterial J o u r n a l P r e -p r o o f Journal Pre-proof pressure of 150 mm Hg, and maximum systolic blood pressure of 237 mm Hg, and encephalopathy ( Figure 1D Table) . She was treated with hydroxychloroquine and tocilizumab ( Figure 1D , blue arrow). Her course was complicated by persistently confusion with intermittent agitation. She followed commands inconsistently. A CT of the head performed for new onset right arm weakness showed hypoattenuation in the parietooccipital white matter bilaterally (Figure 2A) . MRI showed T2 hyperintensity in the bilateral parietooccipital lobes ( Figure 1D ) with corresponding diffusion restriction and foci of susceptibility hypointensity within the areas of T2 hyperintensity ( Figure 2B and 2C). A 48-hour EEG was negative for epileptiform activity. Her blood pressure was controlled, and her confusion and right arm weakness improved. On discharge, she was alert and oriented to person and time but not place and followed commands consistently.

We describe four cases of PRES in critically ill patients with SARS-CoV-2 infection. All four patients had acute kidney injury (AKI) with elevated blood pressure preceding the diagnosis of PRES. Of note, in Case 1 and 2, maximum mean arterial pressure occurred on the day of diagnosis (Figure 1A and 1B) . Neurological findings improved with blood pressure control, and in Case 1 and 2, with seizure control. Three of the four patients were discharged to acute rehabilitation, and the fourth to subacute rehabilitation.

has not yet been well described, though it appears that COVID-19 is associated with multiple risk factors that have been seen in PRES.

Renal failure is a common complication of COVID-19, with 13.3% of those intubated requiring new renal replacement therapy 3 . Among our four patients, all had AKI with elevated blood pressure, though only Case 1 required dialysis. It has been suggested that renal failure is the strongest predictor of the development of PRES, seen in up to 55% of cases 2 .

Another hallmark of critical illness in COVID-19 has been "cytokine storm" with fevers, elevated ferritin, IL-6, and TNF-α 3 . In this regard, ferritin levels were elevated in our patients as were LDH and CRP which are also nonspecific markers of inflammation. IL-6 levels, however, were elevated only in Case 4, although IL-6 was not checked regularly in COVID-19 cases in our institution. D-dimer levels were extremely high as is often the case in association with COVID-19 and with activation of the proinflammatory cytokine cascade in general 6 .

The cytokine storm of COVID-19 may be related to the development of PRES in our patients. TNF-α (not specifically measured in our patients) has been associated with cytokine storm in COVID-19 patients and is implicated in PRES because it increases vascular permeability and upregulates vascular endothelial growth factor (VEGF) in the setting of hypoxia 2, 7 . Elevated levels of VEGF have been found in disease states associated with PRES, most notably SLE 8 . Endothelial injury, which has also been J o u r n a l P r e -p r o o f Journal Pre-proof implicated in PRES and in conditions associated with it such as pre-eclampsia 9 , is prominent in COVID-19; viral inclusion structures have been found on autopsy in the endothelial cells in lungs, heart, kidneys, and liver. Virus is thought to enter cells through the ACE2 receptor 10 .

Immunomodulatory medications such as cyclosporine and tacrolimus are known to induce PRES. Similar treatments used for SARS-CoV-2 infection, such as tocilizumab, which was given to one patient in our series, have also been implicated 11 .

Hydroxychloroquine, which was given to all of the patients in our case series, has been implicated in PRES, though it is unclear if this is an independent risk factor or simply a consequence of the fact that it is used commonly in patients with SLE 12 . The use of hydroxychloroquine in our patients does not distinguish them from other patients with COVID-19 since this drug was used uniformly at our institution in COVID-19 patients during the time period studied here.

The imaging characteristics of PRES have been well described, with the hallmark finding of bilateral hemispheric subcortical and cortical edema. While there is usually a predominance of edema in the bilateral parietoccipital lobes, other areas commonly affected are the frontal lobes, temporo-occipital junction and cerebellum 13,14 .

A Reversible Posterior Leukoencephalopathy Syndrome

Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions

Severe Covid-19

D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients

Vascular endothelial growth factor signaling in hypoxia and inflammation

Vascular endothelial growth factor in systemic lupus erythematosus-correlations with disease activity and nailfold capillaroscopy changes

Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive

Endothelial cell infection and endotheliitis in COVID-19

Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. Arquivos de neuro-psiquiatria

The imaging spectrum of posterior reversible encephalopathy syndrome: a pictorial review

Imaging characteristics associated with clinical outcomes in posterior reversible encephalopathy syndrome

Apparent diffusion coefficient reduction might be a predictor of poor outcome in patients with posterior reversible encephalopathy syndrome